drugset / Trial / NCT07590531
AMT-116 in Combination With Ivosidan in Patients With Lung Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC). The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
Timeline
- Start
- 2026-06-29
- Primary completion
- 2027-05-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AMT-116 | Other / unclassified | — | — |
| Subject | Ivonescimab | Monoclonal antibody | — | — |